Update on the use of dutasteride in the management of benign prostatic hypertrophy
Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0ff1dce861134cfd9c3abd9be8d3c16b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0ff1dce861134cfd9c3abd9be8d3c16b |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0ff1dce861134cfd9c3abd9be8d3c16b2021-12-02T05:03:28ZUpdate on the use of dutasteride in the management of benign prostatic hypertrophy1178-1998https://doaj.org/article/0ff1dce861134cfd9c3abd9be8d3c16b2007-04-01T00:00:00Zhttps://www.dovepress.com/update-on-the-use-of-dutasteride-in-the-management-of-benign-prostatic-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. The combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist reduces the clinical progression of BPH over either class of drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasterideJoe MillerThomas H TarterDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 99-104 (2007) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Geriatrics RC952-954.6 |
spellingShingle |
Geriatrics RC952-954.6 Joe Miller Thomas H Tarter Update on the use of dutasteride in the management of benign prostatic hypertrophy |
description |
Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. The combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist reduces the clinical progression of BPH over either class of drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasteride |
format |
article |
author |
Joe Miller Thomas H Tarter |
author_facet |
Joe Miller Thomas H Tarter |
author_sort |
Joe Miller |
title |
Update on the use of dutasteride in the management of benign prostatic hypertrophy |
title_short |
Update on the use of dutasteride in the management of benign prostatic hypertrophy |
title_full |
Update on the use of dutasteride in the management of benign prostatic hypertrophy |
title_fullStr |
Update on the use of dutasteride in the management of benign prostatic hypertrophy |
title_full_unstemmed |
Update on the use of dutasteride in the management of benign prostatic hypertrophy |
title_sort |
update on the use of dutasteride in the management of benign prostatic hypertrophy |
publisher |
Dove Medical Press |
publishDate |
2007 |
url |
https://doaj.org/article/0ff1dce861134cfd9c3abd9be8d3c16b |
work_keys_str_mv |
AT joemiller updateontheuseofdutasterideinthemanagementofbenignprostatichypertrophy AT thomashtarter updateontheuseofdutasterideinthemanagementofbenignprostatichypertrophy |
_version_ |
1718400692791541760 |